Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
28 Cards in this Set
- Front
- Back
|
What are the four main strategies for approaching treatment of Parkinon's disease
|
(1) Agonize dopamine receptors (pramiprexole, ropinirole, bromocriptine)
(2) Increase dopamine (L-dopa) (3) Prevent dopamine breakdown (selegiline, entacapone) (4) Curb excess cholinergic activity (benzotropine) |
|
|
MOA of bromocriptine
|
DA receptor agonist
|
|
|
MOA of pramipexole
|
DA receptor agonist
|
|
|
MOA of ropinirole
|
DA receptor agonist
(along with bromocriptine and p____) |
|
|
MOA of amantadine
|
Increase DA release
|
|
|
MOA of L-dopa/carbidopa
|
DA analog (L-dopa) and dopa carboxylase inhibitor (prevents activation in the periphery)
|
|
|
MOA of selegiline
|
MAO type B inhibitor; prevents DA breakdown
|
|
|
MOA of entacapone
|
COMT inhibitor; prevents DA breakdown
|
|
|
MOA of tolcapone
|
COMT inhibitor; prevents DA breakdown
|
|
|
MOA of benztropine
|
Antimuscarinic; improves tremor and rigidity but has little effect on bradykinesia
(too much ACh is a problem in Parkinson's; too little ACh is a problem in Alzheimer's) |
|
|
Treatment for essentail tremor
|
Beta blockers
|
|
|
This anti-Parkinson medication is also used as an antiviral against influenze A and rubella
|
Amantadine
|
|
|
Toxicity of amantadine
|
Ataxia
|
|
|
This anti-Parkinson medication improves tremor and rigidity but has little effect on bradykinesia
|
Benztropine
|
|
|
What does dopa decarboxylase do?
|
It is located in the CNS, and converts L-dopa (given pharmaceutically, and able to cross the BBB) to dopamine
|
|
|
Toxicity of L-dopa/carbidopa
|
Arrhythmia (from peripheral conversion to DA), dyskinesia following administration, akinesia between doses
|
|
|
MOA of carbidopa
|
Peripheral dopa decarboxylase inhibitor; limits peripheral side effects and increases availability of L-dopa in the brain
|
|
|
This anti-Parkinson medication may enhance the adverse effects of L-dopa, though it is usually given as an adjunct with L-dopa
|
Selegiline
|
|
|
MOA of sumatriptan
|
5-HT(1b/1d) agonist. Causes vasoconstriction, inhibition of trigeminal activation and vasoactive peptide release
|
|
|
Half-life of sumatriptan
|
Short. Under 2 hours
|
|
|
Indicaitons for sumatriptan
|
Acute migraine, cluster headache attacks
|
|
|
Toxicity of sumatriptan
|
Coronary vasospasm, tingling
|
|
|
This drug is contraindicated in patients with CAD or Prinzmetal's angina
|
Sumatriptan
|
|
|
These two drugs are used in the treatment of Alzheimer's
|
Memantine, donepezil (indirect muscarinic agonist)
|
|
|
MOA of memantine
|
NMDA receptor blocker; prevents excitotoxicity, which is mediated by Ca
|
|
|
Toxicity of memantine
|
Dizziness, confusion, hallucination
|
|
|
MOA of donepezil
|
Acetylcholinesterase inhibitor
|
|
|
Toxicity of donepezil
|
Nausea, dizziness, insomnia
|
